ATRX and central nervous system cancer: Up to 25% of gliomas exhibit ATRX mutations, with specific percentages including 67% of WHO grade II astrocytomas, 73% of WHO grade III astrocytomas, and 57% of secondary glioblastomas (Olar and Sulman, 2015).